Premier, Inc.'s PINC AI Applied Sciences And Datavant Collaborate To Enable Next-Generation Clinical Trials
Portfolio Pulse from Benzinga Newsdesk
Premier, Inc. (PINC) and Datavant are expanding their collaboration to enhance clinical trials by leveraging real-world data and evidence. This partnership aims to improve trial diversity, design, and patient outcomes while reducing costs and time. The collaboration, which began in September 2022, utilizes Datavant's technology to link clinical and real-world data, generating insights that could lead to better patient care and more effective treatments. This effort supports the development of novel therapies by providing a more comprehensive understanding of medical interventions in real-world settings.
February 13, 2024 | 1:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Premier, Inc.'s expanded collaboration with Datavant to leverage real-world data in clinical trials aims to enhance patient outcomes and trial efficiency. This strategic move could position PINC as a leader in healthcare innovation, potentially boosting its market reputation and financial performance.
The expanded collaboration between Premier, Inc. and Datavant is likely to have a positive short-term impact on PINC's stock price. By leveraging real-world data for clinical trials, PINC is positioned at the forefront of healthcare innovation, which could enhance its market reputation and attract investor interest. The initiative's focus on improving patient outcomes, trial diversity, and efficiency, while reducing costs, aligns with broader industry trends and demands, potentially leading to increased revenues and profitability for PINC.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90